Automatic blood grouping analyzer is an analyzer that can forward and reverse ABO blood group, Rh (D) blood group test, irregular antibody screening and cross-matching of blood test. It mainly consists of liquid handling system, incubator, centrifuge, interpretoscope, and microcomputer system.

The global blood coagulation analyzer market is projected to grow at a substantial CAGR of 5.9% over the period 2018 to 2023, driven by its increasing scope, product types, and applications.

Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its liquid biopsy-based ExoDx Prostate IntelliScore (EPI) test in the state.

Beckman Coulter Life Sciences said today it has acquired single-cell data analysis and software-as-a-service company Cytobank for an undisclosed amount.

Resolution Bioscience is the latest in a long line of firms that has been granted breakthrough device designation from FDA. The Kirkland, WA-based company received the designation for its qualitative in vitro diagnostic.

A breach of Quest Diagnostics’ billing collections vendor could have exposed the personal, financial, and medical information of as many as 12 million customers, multiple media outlets are reporting.

There’s a new player in the liquid biopsy field. Thrive Earlier Detection Corp., announced late last month that it has launched and has raised $110 million in its Series A round.

Inivata has developed the InVision platform based on research from the Cancer Research UK Cambridge Institute at the University of Cambridge. Its lead product, InVisionFirst-Lung, is commercially available and was developed to provide molecu

The latest bit of activity comes from Saga Diagnostics, a Lund, Sweden based company that has raised $4.1 million in a financing round. In a release the company said Hadean Ventures, a Nordic focused European life science fund manager, leads

Liquid biopsy has attracted a surge of companies that are trying to change the way cancer is detected and monitored. But the benefits of this new type of technology can - and should - seep into other disease categories.

Upon closing of the transaction, Burlington, the MA-based company will be a subsidiary of Bracco Imaging, led by its current leadership team. Milan, Italy-based Bracco Imaging said Blue Earth Diagnostics will retain the well-established bran